检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.

Nadine Kutsch, Emily Eva Holmes,Sandra Robrecht, Gudrun Schüler,Ursula Vehling-Kaiser,Thomas Decker, Sigrun Müller-Hagen, Karin Heinisch,Sebastian Böttcher,Matthias Ritgen,Karl-Anton Kreuzer,Stephan Stilgenbauer,Anna Maria Fink,Kirsten Fischer,Barbara Eichhorst,Michael Hallek,Clemens-Martin Wendtner

Leukemia & lymphoma（2023）

引用 2|浏览21
暂无评分
关键词
obinutuzumab,refractory cll patients,cyclophosphamide,fludarabine,bendamustine
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要